RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
RenovoRx, Inc.NASDAQ: RNXT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $3.52M (cash outflow) rose 45.5% year over year, ahead of the +20.8% change in trailing-twelve-month net income. Sequentially, it rose 19.7% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.
Context
- Net income amounted to 994.5% of revenue in FY2025, down 19503.2 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$9.27M (-17.0%) for the fiscal year ending Dec 2026, a slowdown from the +26.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.52M+19.7% QoQ
- Last fiscal yearDec 2025
- -$11.17M+26.7% YoY
- LTMMar 2026
- -$12.27M+20.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +45.5% | +6.0% | -39.5 pp |
| 1 year | +26.7% | -17.0% | -43.7 pp |
| 3-year CAGR | +4.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (11.17M) USD
- Year-over-year change
- -26.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.17M) | -26.7% |
| FY2024 | 2024-12-31 | (8.81M) | +13.9% |
| FY2023 | 2023-12-31 | (10.23M) | -3.5% |
| FY2022 | 2022-12-31 | (9.89M) | -56.4% |
| FY2021 | 2021-12-31 | (6.32M) | — |
Net Income vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's LTM Mar 2026 net income of $12.27M is the smallest of the 6 companies compared; the peer median is $34.17M.
- Its year-over-year change of +20.8% is the 4th highest of 5, against a peer median of +31.9%.
- Net income amounts to 824.0% of revenue for RNXT, versus a peer median of 345.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $91.72M | +58.4% | — | 345.4% | |
| LTM Mar 2026 | $40.92M | +40.8% | +944.4% | — | |
| LTM Dec 2025 | $34.17M | — | -4.8% | — | |
| LTM Mar 2026 | $24.25M | +23.1% | +12.4% | — | |
| LTM Mar 2026 | $15.91M | -19.9% | +6.3% | — | |
| LTM Mar 2026 | $12.27M | +20.8% | +4.1% | 824.0% | |
| Peer median (excluding RNXT) | $34.17M | +31.9% | +9.3% | 345.4% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Depreciation & Amortization | 9K | 6K | 0 | 0 | 2K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 147K | 644K | 1.08M | 1.17M | 1.27M |
| Change in Working Capital | (265K) | 428K | 605K | 280K | (247K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (96K) |
| Inventory | 0 | 0 | 0 | 0 | (189K) |
| Accounts Payables | 363K | 9K | 27K | 25K | 213K |
| Other Working Capital | (628K) | 419K | 578K | 255K | (175K) |
| Other Non-Cash Items | 517K | 0 | (1.71M) | (1.77M) | (827K) |
| Operating Cash Flow | (5.92M) | (8.81M) | (10.26M) | (9.13M) | (10.97M) |
| Capital Expenditures | (15K) | 0 | 0 | (12K) | (2K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (8M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 5.97M | 2.03M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (15K) | (2.03M) | 2.03M | (12K) | (2K) |
| Debt Repayment | 1.98M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 14.56M | 42K | 5M | 15.02M | 12.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.79M | 0 | 8K | 102K | (1.3M) |
| Financing Cash Flow | 19.33M | 42K | 5.01M | 15.12M | 10.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 13.4M | (10.8M) | (3.22M) | 5.98M | (130K) |
| Free Cash Flow | (5.93M) | (8.81M) | (10.26M) | (9.14M) | (10.98M) |
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.